
    
      A Phase 1b/2, multicenter, open-label study was designed to evaluate the efficacy and safety
      of acalabrutinib in subjects with recurrent glioblastoma multiforme (GBM) who had progressed
      after one or two prior systemic treatment regimens.
    
  